Prescription ·Strong evidence ·Reviewed May 2026
Solifenacin is an antimuscarinic used for overactive bladder with urgency, frequency, and urge urinary incontinence. It improves bladder storage by relaxing detrusor muscle but can cause dry mouth, constipation, urinary retention, heat intolerance, cognitive effects in susceptible patients, and QT prolongation in high-risk settings.
The bottom line
Evidence rating strong. Most-documented uses: reduction in urinary urgency, reduction in urinary frequency, reduction in urge urinary incontinence episodes. 3 sources indexed (2004–2026), with 4 interaction records on file.
Core mechanism
Solifenacin competitively antagonizes muscarinic receptors, with functional selectivity for bladder M3 receptor-mediated detrusor contraction. Reduced parasympathetic bladder activity increases bladder capacity and decreases urgency episodes. Systemic anticholinergic effects explain dry mouth, constipation, blurred vision, urinary retention, and possible central effects, while CYP3A4 metabolism creates interaction concerns with inhibitors and inducers.1,3
May be taken with or without food. Maintain hydration and bowel regimen if constipation occurs.3
Antimuscarinic slowing of gastrointestinal transit may increase mucosal injury risk from solid oral potassium products.
Recommendation: Use potassium only under clinician guidance; consider non-solid formulations if potassium is necessary and constipation or dysphagia is present.
High-dose quercetin may inhibit CYP3A4 or transporters and could increase solifenacin adverse effects.
Recommendation: Use cautiously and monitor dry mouth, constipation, urinary retention, blurred vision, or palpitations after starting or stopping quercetin.
St. John's Wort can induce CYP3A4 and may reduce solifenacin exposure, decreasing bladder symptom control.
Recommendation: Avoid starting or stopping St. John's Wort without discussing symptom monitoring and alternatives.
Melatonin may add to solifenacin-associated somnolence or dizziness.
Recommendation: Use cautiously in older adults and avoid hazardous tasks if sedated.
Numbered references. Citations throughout the page link here.
Randomized data support reductions in urgency, frequency, and incontinence episodes with solifenacin.
Guideline recommends shared decision-making for antimuscarinics and beta-3 agonists with attention to retention, constipation, and cognitive risks.
Labeling describes 5 to 10 mg dosing, dose limits, contraindications, anticholinergic adverse effects, and QT warning in high-risk patients.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
